Watson Sues FDA To Regain Exclusivity For Generic Actos

Law360, Washington (August 15, 2012, 2:43 PM EDT) -- Generic-drug maker Watson Laboratories Inc. sued the U.S. Food and Drug Administration on Wednesday in Washington federal court, claiming the agency is attempting to rob Watson of a 180-day marketing exclusivity period for a generic version of Takeda North America Inc.'s diabetes drug Actos.

Watson initially filed an abbreviated new drug application to market a generic form of Actos, or pioglitazone, in 2003. In March 2010, the company reached a settlement with Takeda that would allow it, Mylan Inc. and Ranbaxy Laboratories Ltd. to begin selling...
To view the full article, register now.

Documents

Related

Sections

Case Information

Case Title

WATSON LABORATORIES, INC. v. SEBELIUS et al


Case Number

1:12-cv-01344

Court

District Of Columbia

Nature of Suit

Other Statutory Actions

Judge

Amy Berman Jackson

Date Filed

August 15, 2012

Law Firms

Companies

Government Agencies

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.